Amgen receives positive CHMP opinion to expand use of Mimparaź (cinacalcet)
Amgen announced the CHMP of the EMA has adopted a positive opinion for the Marketing Authorization of a pediatric formulation of Mimparaź (cinacalcet). Approval was recommended for treatment of secondary hyperparathyroidism in children aged three years and older with end-stage renal disease. June 23, 2017